These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2000644)

  • 21. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
    Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
    FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic drug metabolism.
    Relling MV
    Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic polymorphism and metabolism of tricyclic antidepressants].
    Samyn B
    Encephale; 1992; 18(6):661-4. PubMed ID: 1342665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
    LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
    Daniel HI; Edeki TI
    Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M
    Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
    [No Abstract]   [Full Text] [Related]  

  • 28. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.
    Gut J; Meier UT; Catin T; Meyer UA
    Biochim Biophys Acta; 1986 Dec; 884(3):435-47. PubMed ID: 3096378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral.
    Raner GM; Vaz AD; Coon MJ
    Mol Pharmacol; 1996 Mar; 49(3):515-22. PubMed ID: 8643091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
    Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
    J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Brøsen K; Skjelbo E; Flachs H
    Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
    Gonzalez FJ
    Birth Defects Orig Artic Ser; 1990; 26(1):17-42. PubMed ID: 2224077
    [No Abstract]   [Full Text] [Related]  

  • 34. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
    Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
    Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.
    Xie HG; Xu ZH; Luo X; Huang SL; Zeng FD; Zhou HH
    Pharmacogenetics; 1996 Jun; 6(3):235-8. PubMed ID: 8807662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical consequences of polymorphic drug oxidation.
    Alván G
    Fundam Clin Pharmacol; 1991; 5(3):209-28. PubMed ID: 1937350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
    Alván G; Bechtel P; Iselius L; Gundert-Remy U
    Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.